Brentuximab vedotin, an antibody–drug conjugate, in patients with CD30‐positive haematologic malignancies and hepatic or renal impairment

AIMS: Brentuximab vedotin, an antibody–drug conjugate (ADC), selectively delivers the microtubule‐disrupting agent monomethyl auristatin E (MMAE) into CD30‐expressing cells. The pharmacokinetics of brentuximab vedotin have been characterized in patients with CD30‐positive haematologic malignancies....

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Baiteng, Chen, Robert, O'Connor, Owen A., Gopal, Ajay K., Ramchandren, Radhakrishnan, Goy, Andre, Matous, Jeffrey V., Fasanmade, Adedigbo A., Manley, Thomas J., Han, Tae H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Clinical Trials
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5089583/
https://www.ncbi.nlm.nih.gov/pubmed/27115790
http://dx.doi.org/10.1111/bcp.12988

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5089583/
https://www.ncbi.nlm.nih.gov/pubmed/27115790
http://dx.doi.org/10.1111/bcp.12988

Ejemplares similares